(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

November 1, 2023


ANV600 combines a unique non-blocking PD-1 targeting approach with an IL-2Rβ/γ selective agonistic principle

The first arm of the bispecific antibody features an αIL-2/IL-2 fusion protein, which effectively prevents IL-2Rα from binding to the cytokine and therefore selectively activates IL-2Rβ/γ.The second arm consists of a high affinity αPD-1antibody to selectively deliver the IL-2Rβ/γ agonist to tumor antigen experienced PD-1+ T cells. The αPD-1arm binds to a unique epitope on PD-1 that enables combination of ANV600 with PD-1 checkpoint inhibitors.

Related products

Catalogue product


The hPD-1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Customized product

No items found.